REGULATED INFORMATION
PRESS RELEASE
Transparency notifications
pursuant to Article 14 of the Law of May 2, 2007
Leuven (Belgium) - May 14, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency notifications pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.
Summary of the notifications
It concerns the following two notifications from SOCIETE GENERALE SA:
1. Content of the first notification by SOCIETE GENERALE SA
Date of the notification: May 8, 2018.
Reason of the notification: acquisition or disposal of voting securities or voting rights.
Person subject to the notification requirement: SOCIETE GENERALE SA (with address at 29 Bd Haussman - 75009 Paris - France), who is a person that notifies alone.
Date on which the threshold was crossed: April 30, 2018.
Threshold that was crossed: 5%.
Denominator: 296,067,856.
Details of the notification: following the acquisition of voting securities or voting rights, the number of voting rights was as follows:
and the number of equivalent financial instruments was as follows:
Total: 14,858,459 voting rights and 72,915 voting rights that may be acquired if the financial instrument is exercised (5.04% of the total number of voting rights).
Chain of controlled undertakings through which the holding is effectively held: SOCIETE GENERALE INTERNATIONAL LIMITED is 100% held by SOCIETE GENERALE SA (holding).
***
2. Content of the second notification by SOCIETE GENERALE SA
Date of the notification: May 8, 2018.
Reason of the notification: acquisition or disposal of voting securities or voting rights.
Person subject to the notification requirement: SOCIETE GENERALE SA (with address at 29 Bd Haussman - 75009 Paris - France), who is a person that notifies alone.
Date on which the threshold was crossed: May 2, 2018.
Threshold that was crossed: 5%.
Denominator: 296,067,856.
Details of the notification: following the disposal of voting securities or voting rights, the number of voting rights was as follows:
and the number of equivalent financial instruments was as follows:
Total: 13,331,320 voting rights and 72,915 voting rights that may be acquired if the financial instrument is exercised (4.53% of the total number of voting rights).
Chain of controlled undertakings through which the holding is effectively held: SOCIETE GENERALE INTERNATIONAL LIMITED is 100% held by SOCIETE GENERALE SA (holding).
This press release and the above-mentioned transparency notifications can be consulted on our website:
For more information:
TiGenix
Claudia Jiménez
Senior Director Investor Relations and Communications
Tel: +34918049264
Claudia.jimenez@tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced biopharmaceutical company developing novel therapies for serious medical conditions by exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells.
TiGenix lead product, Alofisel (darvadstrocel), previously Cx601, received European Commission (EC) approval for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. A global Phase III trial intended to support a future U.S. Biologic License Application (BLA) started in 2017. TiGenix has entered into a licensing agreement with Takeda, a global pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to develop and commercialize Alofisel for complex perianal fistulas outside the U.S. TiGenix' second adipose-derived product, Cx611, is undergoing a Phase I/II trial in severe sepsis - a major cause of mortality in the developed world. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain) and Cambridge, MA (USA). For more information, please visit http://www.tigenix.com.